Key result
Prothrombin complex concentrates (PCC) are the front-line agent for rapid and safe reversal of vitamin K antagonist-related coagulopathy in patients with gastrointestinal hemorrhage.
Why the study?
Vitamin K antagonists have a narrow therapeutic window, mandate frequent monitoring and dose adjustments, and are not free of adverse effects.
This review discusses the management of gastrointestinal hemorrhage in patients receiving warfarin, focusing on reversal agents such as vitamin K and prothrombin complex concentrates.
VKA management in GI bleeding warrants individualized reversal; Level 5 data leaves optimal strategies open for confirmation.
Anticoagulants, including vitamin K antagonists (VKA) are administered in a greeat majority of patients who are in need of prophylaxis and treatment of thromboembolic events allover the world. Many patients benefit from anticoagulant effects of VKA in acute and chronic venous and arterial thromboembolic diseases, although nowadays they have been partly replaced by newly generated direct oral anticoagulants. Treatment with VKA therapy necessitates great caution because of its narrow therapeutic window. These drugs also mandate frequent monitoring and dose adjustments. In brief, these agents are not free of adverse effects.
No takes yet. Share an insight, caveat, or question.
Özgür Karcıoğlu (2020) conducted a review in Gastrointestinal hemorrhage in patients receiving warfarin. Prothrombin Complex Concentrates (PCC) vs. Fresh frozen plasma (FFP) and Vitamin K was evaluated. Prothrombin complex concentrates (PCC) are the front-line agent for rapid and safe reversal of vitamin K antagonist-related coagulopathy in patients with gastrointestinal hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: